SPARC

Why is Sun Pharma Advanced Research Company Ltd falling/rising?

As of 15-Jun, Sun Pharma Advanced Research Company Ltd's stock price has risen to 229.30, reflecting a 2.64% increase. This rise is driven by strong historical performance, positive trading activity, and impressive financial results, including significant growth in net sales and operating profit.

As of 15-Jun, Sun Pharma Advanced Research Company Ltd is experiencing a rise in its stock price, currently at 229.30, which reflects an increase of 5.9 or 2.64%. This upward movement can be attributed to several key factors. <BR><BR>Firstly, the stock has shown strong performance over various periods, with a notable 12.60% increase over the past week and a remarkable 40.16% rise over the last month. Year-to-date, the stock has surged by 70.55, significantly outperforming the broader market, represented by the Sensex, which has declined by 10.51% during the same timeframe. Additionally, the stock has generated a return of 38.22% over the past year, while the market has faced negative returns of -5.98%.<BR><BR>Today's performance indicates that the stock has outperformed its sector by 3%, and it has been on a consecutive gain streak for the last two days, accumulating a total return of 12.11% in this period. The stock also reached an intraday high of Rs 233.8, reflecting a 4.66% increase during the trading day.<BR><BR>Moreover, the stock's trading activity suggests rising investor participation, with a significant increase in delivery volume, which rose by 128.54% compared to the 5-day average. The stock is also trading above its moving averages across multiple timeframes, indicating a strong bullish trend.<BR><BR>The company's financial performance supports this positive sentiment, as it reported an impressive growth in net sales of 21831.6% and an operating profit increase of 141.48%. The strong fundamentals, coupled with a healthy return on capital employed (ROCE) of 83.7, further bolster investor confidence.<BR><BR>In summary, the combination of strong historical performance, positive trading activity, and robust financial results are key reasons for the rising stock price of Sun Pharma Advanced Research Company Ltd.

Which are the latest news on SPARC?

How big is SPARC?

As of 10th June, Sun Pharma Advanced Research Company Ltd has a market capitalization of 6,799.00 Cr, with recent net sales of 1,879.17 Cr and a net profit of 1,553.20 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Sun Pharma Advanced Research Company Ltd has a market capitalization of 6,799.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,879.17 Cr, while the sum of Net Profit for the same period is 1,553.20 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at a loss of 216.95 Cr, and Total Assets are valued at 333.22 Cr.

Who are in the management team of SPARC?

The management team of SPARC includes T Rajamannar, Sudhir V Valia, Bhavna Doshi, Ferzaan Engineer, Robert Spiegel, and Dilip S Shanghvi as the Non-Executive Chairman.

The management team of SPARC includes the following individuals:<BR><BR>1. T Rajamannar - Director<BR>2. Sudhir V Valia - Director<BR>3. Bhavna Doshi - Independent Director<BR>4. Ferzaan Engineer - Independent Director<BR>5. Robert Spiegel - Independent Director<BR>6. Dilip S Shanghvi - Chairman (Non-Executive)<BR><BR>If you need more details about their roles or contributions, feel free to ask!

Who are the peers of the SPARC?

SPARC's peers include Akums Drugs, Blue Jet Health, Supriya Lifesci., Sanofi India, FDC, Aarti Pharma, Senores Pharma, Innova Captab, and Bliss GVS Pharma. SPARC shows excellent growth and average management risk, with a 1-year return of 27.13%, outperforming Blue Jet Health but underperforming Senores Pharma at 117.67%.

Peers: The peers of SPARC are Akums Drugs, Blue Jet Health, Supriya Lifesci., Sanofi India, FDC, Aarti Pharma, Senores Pharma., Innova Captab, and Bliss GVS Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Blue Jet Health, Supriya Lifesci., and Sanofi India, while Average management risk is found at Akums Drugs, SPARC, FDC, Aarti Pharma, Senores Pharma., and Bliss GVS Pharma. Growth is Excellent at SPARC and Senores Pharma., while Below Average growth is noted for Akums Drugs, Blue Jet Health, Supriya Lifesci., Sanofi India, FDC, Aarti Pharma, and Innova Captab. In terms of Capital Structure, Excellent ratings are given to Blue Jet Health, Supriya Lifesci., Sanofi India, and Innova Captab, while Average ratings are assigned to SPARC and Good ratings to Akums Drugs and Senores Pharma., with the rest having Excellent ratings.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Senores Pharma. at 117.67%, while the lowest is Blue Jet Health at -46.94%. SPARC's 1-year return of 27.13% is significantly higher than Blue Jet Health's but lower than Senores Pharma.'s. Additionally, FDC, Aarti Pharma, and Sanofi India have negative six-month returns.

What does SPARC do?

Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical stage bio-pharmaceutical firm focused on developing new drugs and delivery systems, with a market cap of INR 6,799 Cr and a net profit of 1,761 Cr as of March 2026. Key metrics include a P/E ratio of 4.00 and a return on equity of 116.94%.

Overview:<BR>Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical stage bio-pharmaceutical company engaged in creating new drugs and delivery systems within the Pharmaceuticals & Biotechnology industry, classified as a Small Cap.<BR><BR>History:<BR>SPARC was incorporated on March 1, 2006, as an innovative and development company. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,853 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 1,761 Cr (Quarterly Results - Mar 2026)<BR>- Market cap: INR 6,799 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 4.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.42<BR>- Return on Equity: 116.94%<BR>- Price to Book: 5.07<BR><BR>Contact Details:<BR>Address: Sun Pharma Advanced Res Centre, Akota Road Akota Vadodara Gujarat : 390020 <BR>Tel: 91-265-2330815/2339257 <BR>Email: secretarial@sparcmail.com <BR>Website: http://www.sparc.life

Should I buy, sell or hold Sun Pharma Advanced Research Company Ltd?

Are Sun Pharma Advanced Research Company Ltd latest results good or bad?

Sun Pharma Advanced Research Company Ltd's latest results show a significant net profit driven by a one-time gain, but the underlying operational performance remains weak, with persistent losses and a negative net worth, indicating ongoing challenges for the company.

The latest results for Sun Pharma Advanced Research Company Ltd (SPARC) present a mixed picture. In Q4 FY26, the company reported a significant net profit of ₹1,761.34 crores, which is a remarkable increase compared to the previous quarter. However, this figure is largely driven by a one-time gain, which has raised concerns about the sustainability of this performance.<BR><BR>Net sales also saw an extraordinary increase of 21,831.60% quarter-on-quarter, reaching ₹1,853.22 crores. This surge is primarily attributed to a one-time transaction, likely related to licensing or asset divestment, rather than a reflection of ongoing operational success. In contrast, the company had been experiencing consistent losses in prior quarters, with net losses ranging from ₹51.87 crores to ₹107.33 crores.<BR><BR>While the operating margin and PAT margin showed dramatic improvements, these metrics are inflated due to the exceptional nature of the recent gains. The underlying operational performance remains concerning, as the company has a negative net worth of ₹216.95 crores and has been burning through cash, with operating cash flow remaining deeply negative.<BR><BR>In summary, while the latest results may appear strong on the surface due to the one-time gain, they do not indicate a sustainable turnaround for the company. The persistent operational losses and negative net worth suggest that SPARC is still facing significant challenges ahead.

When is the next results date for Sun Pharma Advanced Research Company Ltd?

The next results date for Sun Pharma Advanced Research Company Ltd is 18 May 2026.

The next results date for Sun Pharma Advanced Research Company Ltd is scheduled for 18 May 2026.

Is SPARC technically bullish or bearish?

As of November 27, 2025, the trend is mildly bearish due to daily moving averages and weekly Bollinger Bands indicating bearish sentiment, despite mixed signals from the MACD and KST, suggesting a cautious approach.

As of 27 November 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish sentiment and the weekly Bollinger Bands also showing a mildly bearish outlook. The MACD on the weekly is mildly bullish, but the monthly remains bearish, creating a mixed signal. The KST aligns with the weekly MACD, being mildly bullish, while the OBV is mildly bearish on the weekly timeframe. Overall, the lack of strong bullish signals and the presence of bearish indicators suggest a cautious approach.

How has been the historical performance of SPARC?

SPARC has experienced a significant decline in financial performance over the past three years, with net sales dropping from 238.78 crore in March 2023 to 71.77 crore in March 2025, and operating losses worsening from -203.18 crore to -321.35 crore in the same period. Overall, the company's financial metrics indicate ongoing operational challenges.

Answer:<BR>The historical performance of SPARC shows a significant decline in key financial metrics over the past three years, particularly in net sales, operating profit, and net profit.<BR><BR>Breakdown:<BR>SPARC's net sales decreased from 238.78 crore in March 2023 to 75.55 crore in March 2024, and further down to 71.77 crore in March 2025. The total operating income followed a similar trend, dropping from 238.78 crore in March 2023 to 71.77 crore in March 2025. The company faced substantial operating losses, with operating profit (PBDIT) worsening from -203.18 crore in March 2023 to -321.35 crore in March 2025. Profit before tax also reflected this negative trend, moving from -222.58 crore in March 2023 to -342.78 crore in March 2025. Consequently, profit after tax showed a similar decline, falling from -222.58 crore in March 2023 to -342.51 crore in March 2025. The company's total liabilities decreased from 830.13 crore in March 2023 to 333.22 crore in March 2025, while total assets also fell from 830.13 crore to 333.22 crore in the same period. Cash flow from operating activities remained negative, with a cash outflow of -360 crore in March 2025 compared to -429 crore in March 2024. Overall, SPARC's financial performance has deteriorated significantly over the years, indicating ongoing challenges in its operations.

How has been the historical performance of SPARC?

SPARC has faced significant financial challenges over the past three years, with net sales declining from 238.78 Cr in March 2023 to 71.77 Cr in March 2025, and increasing losses reflected in negative operating profit and profit after tax. Despite some cost control efforts, the company has seen a substantial decrease in total assets and liabilities, alongside persistent negative cash flow from operating activities.

Answer:<BR>The historical performance of SPARC shows significant challenges over the past three years, particularly in terms of revenue and profitability.<BR><BR>Breakdown:<BR>SPARC's net sales have declined sharply from 238.78 Cr in March 2023 to 75.55 Cr in March 2024, and further to 71.77 Cr in March 2025. Total operating income followed a similar trend, decreasing from 238.78 Cr in March 2023 to 71.77 Cr in March 2025. The company's total expenditure, excluding depreciation, decreased from 452.84 Cr in March 2023 to 394.91 Cr in March 2025, indicating some cost control efforts. However, operating profit (PBDIT) remained negative, worsening from -203.18 Cr in March 2023 to -321.35 Cr in March 2025. The profit before tax also showed a negative trend, moving from -222.58 Cr in March 2023 to -342.78 Cr in March 2025. Consequently, the profit after tax reflected similar losses, with figures of -222.58 Cr, -387.21 Cr, and -342.51 Cr for the respective years. The company's total liabilities decreased from 830.13 Cr in March 2023 to 333.22 Cr in March 2025, while total assets also fell from 830.13 Cr to 333.22 Cr in the same period. Cash flow from operating activities remained negative, with -360.00 Cr in March 2025, although cash flow from investing activities turned positive at 157.00 Cr. Overall, SPARC's financial performance indicates a trend of declining sales and increasing losses, alongside a significant reduction in total assets and liabilities.

Who are the top shareholders of the SPARC?

The top shareholders of SPARC include Shanghvi Finance Private Ltd with 42.28%, followed by individual investors at 18.99%, and the Sun Pharmaceutical Industries Key Employees Benefit Trust at 3.18%. Mutual funds and foreign institutional investors hold 1.01% and 1.45%, respectively, with no pledged promoter holdings.

The top shareholders of SPARC include the promoters, with Shanghvi Finance Private Ltd holding the largest stake at 42.28%. There are no pledged promoter holdings. In addition, mutual funds hold a total of 1.01% through 10 schemes, while foreign institutional investors (FIIs) account for 1.45% through 31 different FIIs. The highest public shareholder is the Sun Pharmaceutical Industries Key Employees Benefit Trust, which holds 3.18%. Individual investors collectively own 18.99% of the company.

Has SPARC declared dividend?

No Dividend History Available